Last updated: 2026-09-29 21:24:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Nexalin Technology, Inc. (NXL) operates in the ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $4.43, with a market capitalisation of $3.54M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $4.00 to $60.00. This page covers its latest market performance, valuation, price trends and company information.
$3.54M | |
$4.60 | |
$1,016.40 | |
$4.00 | |
$4.27 | |
63.10K | |
9.98K | |
-- | |
$60.00 | |
$4.00 | |
-- | |
-- |
Nexalin Technology, Inc. (NXL) is trading at $4.44 in after-hours trading as of 2026-09-29 20:52:00, up 4.07% ($0.17) from the regular-session close of $4.27.
After-hours trading shows how investors are pricing NXL after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Nexalin Technology, Inc. (NXL) moved from $4.27 to $4.43, representing a gain of 3.75% ($0.16).
The stock traded between $4.00 and $5.25 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 7.24 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0.8%
NXL is currently trading at $4.43, placing it 0.8% of the way from its 52-week low of $4.00 to its 52-week high of $60.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company operates as a single operating and reportable segment, focused on the design and development of innovative neurostimulation products. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the USA and China, with China generating the maximum sales.
| Industry | ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS |
| Employees | 8 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Nexalin Technology, Inc. (NXL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.